

Measurable Costs - Antimicrobial Management Team Pilot Plan

IV to PO Conversions

DRUG	Dose	Cost IV	Cost PO	Cost differential	Potential % Conversion	Potential Annual Cost Savings with Conversion	
Linezolid	600 mg	XXX	XXX	\$ 14.00	40%	\$ 40,114.92	
Voriconazole	200 mg	XXX	XXX	\$ 56.00	30%	\$ 88,402.99	
						80% accounted for by adult population	
ESTIMATED TOTAL						\$ 128,517.91	\$ 102,814.33

Decreasing Antibiotic Durations

(TOP 10 antibiotics by \$)	2005 Annual IV Cost	Reduction by 1 day	Potential Cost Savings by Reduction	
Piperacillin/tazobactam	XXX	XXX	\$ 134,960.48	
Imipenem	XXX	XXX	\$ 27,983.23	
Linezolid	XXX	XXX	\$ 28,366.96	
Ceftriaxone	XXX	XXX	\$ 40,756.43	
Tobramycin	XXX	XXX	\$ 4,331.12	
Levofloxacin	XXX	XXX	\$ 20,633.05	
Meropenem	XXX	XXX	\$ 10,310.61	
Azithromycin	XXX	XXX	\$ 11,502.25	
Aztreonam	XXX	XXX	\$ 9,416.12	
Cefepime	XXX	XXX	\$ 10,756.70	
			80% accounted for by adult population	
ESTIMATED TOTAL			\$ 299,016.95	\$ 239,213.56

Limiting IV Vancomycin Duration

IV Vancomycin	2005 Annual IV Cost	Decrease in duration by 7%*	
	XXX	\$ 4,234.79	
		80% accounted for by adult population	
ESTIMATED TOTAL		\$ 4,234.79	\$ 3,387.83

*Estimated average 7-day course

** Potential to decrease duration by 1 day in 50% of patients